Passage Bio (PASG) Set to Release Quarterly Earnings on Monday

Passage Bio (NASDAQ:PASG) is anticipated to announce its Q3 2026 resultson Monday, November 9th. Analysts expect Passage Bio to post earnings of ($2.43) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Passage Bio (NASDAQ:PASG) last issued its quarterly earnings results on Monday, August 10th. The company reported ($2.44) EPS for the quarter, meeting the consensus estimate of ($2.44). On average, analysts expect Passage Bio to post ($9.78) EPS for the current fiscal year and ($10.20) EPS for the next fiscal year.

Passage Bio Price Performance

PASG opened at $3.45 on Monday. The business has a fifty day moving average price of $4.27 and a 200 day moving average price of $6.35. Passage Bio has a 12 month low of $3.29 and a 12 month high of $20.00. The stock has a market capitalization of $11.10 million, a price-to-earnings ratio of -0.30 and a beta of 1.40.

Analyst Ratings Changes

Several analysts have recently weighed in on PASG shares. Wall Street Zen downgraded shares of Passage Bio from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings cut Passage Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Passage Bio currently has a consensus rating of “Hold” and an average price target of $13.25.

Passage Bio Company Profile

Passage Bio, Inc is a clinical-stage biotechnology company focused on developing gene therapies for diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies to develop treatments intended to address the underlying genetic causes of severe neurological and neurodegenerative disorders.

Its research programs have included PBGM01, an investigational gene therapy for GM1 gangliosidosis, a rare inherited disorder caused by mutations affecting the GLB1 gene.